Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review

References

• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12:s3-9
   PubMed Web of Science ®Google Scholar
• DiPiro JT, Schade RR. Inflammatory bowel disease. In: DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: a Pathophysiologic Approach, 6th edn. New York: McGraw-Hill, 2005:1007-21
   Google Scholar
• Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Ailment Pharmacol Ther 2007;25:861-70
   PubMed Web of Science ®Google Scholar
• Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol 2000;95:1955-60
   PubMed Web of Science ®Google Scholar
• Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000;47:57-70
   PubMedGoogle Scholar
• Roifman I, Sun YC, Fedwick JP, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009;7:175-82
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Medical management of Crohn’s disease: treatment algorithms 2009. Dig Dis 2009;27:536-41
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105;501-23
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465-83
   PubMed Web of Science ®Google Scholar
• Cury DB, Cury MS, Elias GVH, et al. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 2009;15:1771-3
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al, and the ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398-405
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH, et al. for the Crohn’s disease cA2 study group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997;337:1029-35
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009;58:940-8
   PubMed Web of Science ®Google Scholar
• Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008;27:308-15
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. for the CDP870 Crohns’s Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005;129:807-18
   PubMed Web of Science ®Google Scholar
• Remicade: Package Insert. Malvern, PA: Centocor Ortho Biotech, Inc.; 2010
   Google Scholar
• Humira: Package Insert. North Chicago, IL: Abbott Laboratories; 2009
   Google Scholar
• Cimzia: Package Insert. Smyrna, GA: UCB, Inc.; 2009
   Google Scholar
• Suarez D, Haro JM, Novick D, et al. Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia. Pharmacopsychiatry 2009;42:135-40
   PubMed Web of Science ®Google Scholar
• Waters H, Meekins T, Bewtra A, et al. Real-world dosing of anti-tumor necrosis factor therapies in the treatment of adults with Crohn’s disease. J Manag Care Pharm 2008;14:691
   Google Scholar
• Nair KV, Tang B, Van Den Bos J, et al. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin 2009;25:303-14
   PubMed Web of Science ®Google Scholar
• Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease—modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28:76-87
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ananthakrishnan AN, Issa M, et al. Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn’s disease. Inflamm Bowel Dis 2010; published online 18 November 2009, doi:10.1002/ibd.21164
   PubMedGoogle Scholar
• Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9
   PubMed Web of Science ®Google Scholar
• Taxonera C, Rodrigo L, Casellas F, et al. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn’s disease. J Clin Gastroenterol 2009;43:950-6
   PubMedGoogle Scholar